secwatch / observer
8-K filed May 7, 2026, 7:59 PM ET ticker HALO CIK 0001159036
other material confidence high sentiment neutral materiality 0.15

Halozyme stockholders elect directors, approve say-on-pay, ratify auditor

HALOZYME THERAPEUTICS, INC.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

HALOZYME THERAPEUTICS, INC. shareholders approved Ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-05 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-05-05
Exact text from the filing
Proposal 3: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows: Votes For Votes Against Abstain Broker Non-Votes 103,197,579 849,433 91,232 --- The foregoing proposal was approved.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

HALOZYME THERAPEUTICS, INC. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-05-05 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-05-05
Exact text from the filing
Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 84,682,518 9,311,426 255,081 9,889,219 The foregoing proposal was approved.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

HALOZYME THERAPEUTICS, INC. shareholders approved Election of two Class I directors to hold office for a three-year term expiring at the 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified at the 2026-05-05 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-05-05
Exact text from the filing
Proposal 1 : Election of two Class I directors to hold office for a three-year term expiring at the 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified: Names Votes For Votes Against Abstain Broker Non-Votes Bernadette Connaughton 89,053,734 5,068,160 127,131 9,889,219 Matthew L. Posard 82,739,433 10,236,878 1,272,714 9,889,219 Each of the foregoing candidates was elected and each received affirmative votes from more than a majority of the outstanding shares.
View on SEC.gov

560 shareholder votes filed in the last 30 days. Browse all shareholder votes →

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR
accession 0001159036-26-000057
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.